|
|
Vaccine Detail
|
V503 |
| Vaccine Information |
- Vaccine Name: V503
- Target Pathogen: Human Papillomavirus
- Target Disease: HPV infection
- Product Name: Human Papillomavirus 9vHPV (6,11,16,18,31,33,45,52,58) Nonvalent Vaccine, Recombinant
- Tradename: Gardasil
- Manufacturer: Merck Sharp & Dohme LLC
- Type: Recombinant vector vaccine
- Status: Licensed
- Location Licensed: USA
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
- Approved Age for Licensed Use: Females: 16-26 yrs Males:9-15 yrs
- Description: Instead of a 4VHPV, this vaccine is a 9 valent HPV vaccine providing more protection.
|
| Host Response |
|
Human Response
- Vaccination Protocol: Participants (n = 600) were randomized to receive 9vHPV or qHPV vaccines on day 1, month 2 and month 6.
- Description: immune responses to HPV 31/33/45/52/58, a 3-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccine in girls aged 9–15 years after month 7 (Vesikari et al., 2015).
|
| References |
Vesikari et al., 2015: Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. The Pediatric infectious disease journal. 2015; 34(9); 992-998. [PubMed: 26090572].
|
|
